Quince Therapeutics, Inc. (IRLA) AI Dilution Summary

Estimated cash was $93,001,170 as of 2026-10-16, from $115,981,000 at 2026-06-30, against estimated monthly burn of $6,295,667. Funding runs through an active ATM with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC, authorised to $75,000,000 with $27,500,000 sold to date; the most recent capital raised was a $115,000,000 gross private placement of preferred stock closed 2026-05-21.